Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    Green360 Secures Holcim as First Commercial Eco-Clay Customer in Major Validation Milestone
    • News

  • Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    Aerometrex Expands MetroMap Partner Program as Scalable Model Gains Traction
    • News

  • Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    Middle East Conflict Starts to Hurt Corporate Earnings Outlooks
    • News

  • European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    European Lithium and Critical Metals Secure Control of Tanbreez Rare Earth Project
    • News

  • Harris Technology’s refurbished boom signals FY26 profit inflection
    Harris Technology’s refurbished boom signals FY26 profit inflection
    • News

MedAdvisor engaged with $4m deal to promote COVID-19 vaccination

  • In News
  • November 2, 2021
  • Alfred Chan
MedAdvisor engaged with $4m deal to promote COVID-19 vaccination

While Australia enjoys the freedom of restrictions opening up and a substantial decrease in the COVID-19 deaths, vaccination rates across various States in the US remain dangerously low which has prompted one big pharma company to engage medtech company MedAdvisor (ASX: MDR) to slay the anti-vaxxers. 

For the unnamed big pharma company which has a market cap of more than $200 billion, it is hoped that MedAdvisor’s marketing efforts within under-vaccinated populations will help increase vaccination rates. Such promotional work will be delivered in the form of education around the availability and benefits of the COVID-19 vaccination. 

To run the program, MedAdvisor will be paid $4 million (USD $3m) to execute the digital awareness campaign. 

“COVID-19 vaccination rates vary substantially across different states in the US and there are a number of geographies and particular demographics that will benefit from text messages to educate patients on the availability of vaccines,” said MedAdvisor Managing Director, Robert Read. 

“This is our largest digital program in the US to date and if successful would scale well across our network.” 

The deal comes in the form of a Statement of Work which will be launched on MedAdvisor’s inMotion digital platform and is being labelled initially as a pilot program. 

MedAdvisor’s flagship product is software that provides users with access to a virtual pharmacists on their smartphone or tablet. The app connects users to their local pharmacy which can deliver advice on medication, offer pop up reminders and make prescription refill requests. 

In Australia, MedAdvisor has more than 65% of pharmacies listed on their platform which has connected with more than 2.3 million patients. 

Expansion in the United States has been part of MedAdvisor’s long term plan to capitalise on the hugely lucrative US pharmaceuticals market with MedAdvisor already working with more than 25,000 American pharmacies. 

Last month, MedAdvisor confirmed that Walmart had signed on for customer engagement via the platform which will include the full suite of its adherence solutions including digital, in-pharmacy print and direct mail solutions to Walmart customers. Walmart will also participate in Dynamic Engagement adding further digital scale to the MedAdvisor US network. 

MedAdvisor estimates that there are approximately 180 million accessible patients in the United States that they can connect to pharmacies for increased healthcare awareness and medication adherence. 

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • ASX: MDR
  • COVID-19
  • MDR
  • MedAdvisor
  • pharmaceuticals
  • Robert Read
  • vaccine
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.